COMMUNIQUÉS West-GlobeNewswire

Histogenics Corporation to Present at Needham & Company’s 17th Annual Healthcare Conference
19/03/2018
WALTHAM, Mass., March 19, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq: HSGX ), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored [...]
American Gene Technologies Gains Additional Immuno-Oncology Patent
19/03/2018
ROCKVILLE, Md., March 19, 2018 (GLOBE NEWSWIRE) -- American Gene Technologies International Inc. (AGT), a leading gene and cell therapy company, today announced receipt of a second immuno-oncology patent on the [...]
Cellectar Biosciences Granted Orphan Drug Designation for CLR 131 to Treat Neuroblastoma
19/03/2018
MADISON, Wis., March 19, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq: CLRB ), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment [...]
Sorrento Therapeutics Welcomes Jiong Shao as Chief Financial Officer and Reaffirms Intent to Seek Nasdaq/HKSE Dual Listing in 2018
19/03/2018
SAN DIEGO, March 19, 2018 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE ) ("Sorrento") announced today that it appointed Mr Jiong Shao as Executive Vice President and Chief Financial Officer. Jiong is an [...]
Corium to Present at the 17th Annual Needham Healthcare Conference
19/03/2018
MENLO PARK, Calif., March 19, 2018 (GLOBE NEWSWIRE) -- Corium International, Inc. (Nasdaq: CORI ), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty [...]
Collegium Announces the Appointment of Shirley Kuhlmann as General Counsel
19/03/2018
CANTON, Mass., March 19, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL ) today announced the appointment of Shirley Kuhlmann to the newly created position of Executive Vice President and General [...]
resTORbio Announces Formation of Clinical Advisory Board
19/03/2018
Esteemed Experts Engaged as Company Advances Clinical Development Program Phase 2b Data for Lead Program Expected in the Second Half of 2018 BOSTON, March 19, 2018 (GLOBE NEWSWIRE) -- resTORbio, Inc. (NASDAQ: TORC ) [...]
MannKind Announces Participation at the H.C. Wainwright Annual Global Life Sciences Conference
19/03/2018
WESTLAKE VILLAGE, Calif., March 19, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD ) focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as [...]
Catalyst Biosciences to Present at The Needham and Company 17th Annual Healthcare Conference
19/03/2018
SOUTH SAN FRANCISCO, Calif., March 19, 2018 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO ), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology [...]
Fibrocell Reports 2017 Financial Results and Recent Highlights
19/03/2018
- Company to Host Conference Call and Webcast Today at 8:30 a.m. EDT - EXTON, Pa., March 19, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ: FCSC ), a gene therapy company focused on transformational [...]
Cellectar Biosciences to Host 2017 Financial Results and Business Update Conference Call on March 22, 2018
19/03/2018
MADISON, Wis., March 19, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq: CLRB ), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment [...]
Mersana Strengthens Board of Directors Leadership with Appointment of Willard H. Dere, M.D., Professor at the University of Utah and Retired Chief Medical Officer of Amgen
19/03/2018
CAMBRIDGE, Mass., March 19, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN ), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates ( [...]
Denali Therapeutics Announces First-In-Human Dosing Of Its RIPK1 Inhibitor Clinical Program And The Appointment Of Peter Klein To Board Of Directors; Reports Fourth Quarter And Full Year 2017 Financial Results And Business Highlights
19/03/2018
SOUTH SAN FRANCISCO, Calif., March 19, 2018 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI ), a biopharmaceutical company developing a broad portfolio of therapeutic candidates for neurodegenerative diseases [...]
INSYS Therapeutics Reiterates Commitment to Compliant and Ethical Business Practices and Advancing Innovative Product Pipeline
19/03/2018
PHOENIX, March 19, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY ), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today released [...]
US Food and Drug Administration (FDA) provides communication to Spectral
19/03/2018
TORONTO, March 19, 2018 (GLOBE NEWSWIRE) -- Spectral Medical Inc., (TSX: EDT ), a Phase III company developing the first targeted treatment for patients with septic shock today announced that the FDA has determined that [...]
BeyondSpring Announces Initiation of Phase 3 Clinical Development for Plinabulin for Prevention of Chemotherapy-Induced Neutropenia
19/03/2018
NEW YORK, March 19, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI ), a global, clinical-stage biopharmaceutical company focused on the development of transformative cancer therapies, today announced that the [...]
Dova Pharmaceuticals Signs Exclusive Distribution Agreement with Fosun Pharma For Mainland China and Hong Kong
19/03/2018
DURHAM, N.C., March 19, 2018 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA ), a pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for rare diseases where there [...]
Aclaris Therapeutics Announces Positive Update on Phase 2 Results after a 3-month Follow-Up of A-101 45% Topical Solution for Potential Treatment of Common Warts
19/03/2018
Primary, secondary, and exploratory endpoints of Phase 2 trial met during 8-week treatment period After treatment completed, greater improvement vs. placebo observed in 3-month post-treatment follow-up evaluation If [...]
Share buy-back week 11/2018
19/03/2018
Announcement 19 March 2018 Coloplast – transactions in connection with share buy-back programme As mentioned in Announcement No. 3/2018 Coloplast has initiated the first part of the share buy-back programme totalling up [...]

Pages